MedTrace Logo

Optimized Angiomammography and Comparison With Standard Angiomammography

NCT03155386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-01

No results posted yet for this study

Summary

This study will be proposed consecutively to any patient who angiomammography examination was requested by the clinician in charge of patient. A randomization will be performed between an angiomammography examination Standard (SenoBright®) and an optimized angiomammography examination.

A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:

* The intensity of lesion enhancement
* The presence and type of artefacts on the recombined images.
* The quality of low-energy images according to recognized criteria for mammography.

The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions

Conditions

  • Patients for Whom an Angiomammogram Examination is Requested Whether Its Indication

Interventions

OTHER

Angiommamography

A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate: * The intensity of lesion enhancement * The presence and type of artefacts on the recombined images. * The quality of low-energy images according to recognized criteria for mammography. The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-18
Primary Completion
2019-10-04
Completion
2019-10-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03155386 on ClinicalTrials.gov